Treatment trajectories of patients with borderline personality disorder prescribed pharmacotherapy: real-world insights from a retrospective observational study - PubMed
4 hours ago
- #Polypharmacy
- #Pharmacotherapy
- #Borderline personality disorder
- Borderline personality disorder (BPD) lacks approved pharmacological treatments, leading to high morbidity.
- A retrospective observational study analyzed treatment trajectories of BPD patients using real-world data from electronic health records.
- Antidepressants were the most prescribed medication at baseline (80.4%), followed by second-generation antipsychotics (SGAs), anxiolytics, and mood stabilizers.
- Commonly prescribed medications included sertraline, fluoxetine, citalopram (antidepressants), lamotrigine, gabapentin, valproate (mood stabilizers), and quetiapine, aripiprazole (SGAs).
- Polypharmacy (≥1 psychotropic medication) was observed in 83.1% of patients at baseline and increased over time and with age.
- The study highlights a misalignment between clinical practices and BPD treatment guidelines, indicating a significant treatment burden for patients.
- Limitations include the absence of psychotherapy data and reliance on prescription records without adherence information.
- The findings underscore the need for better understanding of BPD neurobiology to improve pharmacological strategies and patient outcomes.